Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide

被引:16
作者
Doki, Kosuke [1 ,2 ]
Darwich, Adam S. [2 ]
Achour, Brahim [2 ]
Tornio, Aleksi [3 ]
Backman, Janne T. [3 ]
Rostami-Hodjegan, Amin [2 ,4 ]
机构
[1] Univ Tsukuba, Fac Med, Dept Pharmaceut Sci, Ibaraki, Japan
[2] Univ Manchester, Ctr Appl Pharmacokinet Res, Div Pharm & Optometry, Manchester, Lancs, England
[3] Univ Helsinki, Dept Clin Pharmacol, Helsinki, Finland
[4] Simcyp Ltd, Sheffield, S Yorkshire, England
关键词
correlation; drug-drug interactions; interindividual variability; PBPK model; repaglinide; IN-VIVO EXTRAPOLATION; PLASMA-CONCENTRATIONS; GEMFIBROZIL; PHARMACOKINETICS; METABOLISM; CYP2C8; VITRO; CYTOCHROME-P450; TRANSPORTERS; VARIABILITY;
D O I
10.1111/bcp.13533
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AimsStatistically significant positive correlations are reported for the abundance of hepatic drug-metabolizing enzymes. We investigate, as an example, the impact of CYP3A4-CYP2C8 intercorrelation on the predicted interindividual variabilities of clearance and drug-drug interactions (DDIs) for repaglinide using physiologically based pharmacokinetic (PBPK) modelling. MethodsPBPK modelling and simulation were employed using Simcyp Simulator (v15.1). Virtual populations were generated assuming intercorrelations between hepatic CYP3A4-CYP2C8 abundances derived from observed values in 24 human livers. A repaglinide PBPK model was used to predict PK parameters in the presence and absence of gemfibrozil in virtual populations, and the results were compared with a clinical DDI study. ResultsCoefficient of variation (CV) of oral clearance was 52.5% in the absence of intercorrelation between CYP3A4-CYP2C8 abundances, which increased to 54.2% when incorporating intercorrelation. In contrast, CV for predicted DDI (as measured by AUC ratio before and after inhibition) was reduced from 46.0% in the absence of intercorrelation between enzymes to 43.8% when incorporating intercorrelation: these CVs were associated with 5th/95th percentiles (2.48-11.29 vs. 2.49-9.69). The range of predicted DDI was larger in the absence of intercorrelation (1.55-77.06) than when incorporating intercorrelation (1.79-25.15), which was closer to clinical observations (2.6-12). ConclusionsThe present study demonstrates via a systematic investigation that population-based PBPK modelling incorporating intercorrelation led to more consistent estimation of extreme values than those observed in interindividual variabilities of clearance and DDI. As the intercorrelations more realistically reflect enzyme abundances, virtual population studies involving PBPK and DDI should avoid using Monte Carlo assignment of enzyme abundance.
引用
收藏
页码:972 / 986
页数:15
相关论文
共 33 条
  • [1] Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis
    Achour, Brahim
    Barber, Jill
    Rostami-Hodjegan, Amin
    [J]. DRUG METABOLISM AND DISPOSITION, 2014, 42 (08) : 1349 - 1356
  • [2] Simultaneous Quantification of the Abundance of Several Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzymes in Human Liver Microsomes Using Multiplexed Targeted Proteomics
    Achour, Brahim
    Russell, Matthew R.
    Barber, Jill
    Rostami-Hodjegan, Amin
    [J]. DRUG METABOLISM AND DISPOSITION, 2014, 42 (04) : 500 - 510
  • [3] Translational value of liquid chromatography coupled with tandem mass spectrometry-based quantitative proteomics for in vitro-in vivo extrapolation of drug metabolism and transport and considerations in selecting appropriate techniques
    Al Feteisi, Hajar
    Achour, Brahim
    Rostami-Hodjegan, Amin
    Barber, Jill
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (09) : 1357 - 1369
  • [4] Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions
    Backman, Janne T.
    Filppula, Anne M.
    Niemi, Mikko
    Neuvonen, Pertti J.
    [J]. PHARMACOLOGICAL REVIEWS, 2016, 68 (01) : 168 - 241
  • [5] CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe
    Backman, Janne T.
    Honkalammi, Johanna
    Neuvonen, Mikko
    Kurkinen, Kaisa J.
    Tornio, Aleksi
    Niemi, Mikko
    Neuvonen, Pertti J.
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (12) : 2359 - 2366
  • [6] Determination of a Quantitative Relationship between Hepatic CYP3A5*1/*3 and CYP3A4 Expression for Use in the Prediction of Metabolic Clearance in Virtual Populations
    Barter, Z. E.
    Perrett, H. F.
    Yeo, K. Rowland
    Allorge, D.
    Lennard, M. S.
    Rostami-Hodjegan, A.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2010, 31 (8-9) : 516 - 532
  • [7] Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
    Darwich, A. S.
    Ogungbenro, K.
    Vinks, A. A.
    Powell, J. R.
    Reny, J-L
    Marsousi, N.
    Daali, Y.
    Fairman, D.
    Cook, J.
    Lesko, L. J.
    McCune, J. S.
    Knibbe, C. A. J.
    de Wildt, S. N.
    Leeder, J. S.
    Neely, M.
    Zuppa, A. F.
    Vicini, P.
    Aarons, L.
    Johnson, T. N.
    Boiani, J.
    Rostami-Hodjegan, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (05) : 646 - 656
  • [8] Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling
    de Zwart, L.
    Snoeys, J.
    De Jong, J.
    Sukbuntherng, J.
    Mannaert, E.
    Monshouwer, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (05) : 548 - 557
  • [9] Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria
    Doki, Kosuke
    Darwich, Adam S.
    Patel, Nikunjkumar
    Rostami-Hodjegan, Amin
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 109 : 111 - 120
  • [10] Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption
    Harwood, M. D.
    Neuhoff, S.
    Carlson, G. L.
    Warhurst, G.
    Rostami-Hodjegan, A.
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (01) : 2 - 28